Cross-posted with permission from Professor Osenga’s December 8, 2025, LinkedIn article<\/a><\/p>\n\n\n\n I\u2019ve seen a lot of misinformation circulating online lately about patents and their role in drug prices. Some articles \u2013 like this one<\/a> \u2013 claim that so-called \u201cpatent thickets\u201d are an abusive strategy drug companies use to keep prices high. The idea is that a brand-name medicine is surrounded by dozens of overlapping patents, supposedly making it impossible for generic manufacturers to enter the market once the initial patents expire.<\/p>\n\n\n\n It\u2019s an attention-grabbing narrative. It\u2019s also deeply misleading.<\/p>\n\n\n\n The premise behind the patent-thicket argument is that a large number of patents signals something nefarious \u2013 that multiple patents must mean companies are gaming the system. But in practice, multiple patents often reflect continued innovation that happens after a drug is approved, not an attempt to block competition.<\/p>\n\n\n\n Consider how medicines evolve. A drug rarely stays static once it reaches the market. Researchers spend years, sometimes decades, finding new ways to improve how a therapy works, how it\u2019s delivered, or which patients it can help. Botox is a well-known example: it was initially<\/a> approved for two rare eye disorders. Today it has more than ten approved uses, from chronic migraine to spasticity. Those advancements required research, clinical trials, and, yes, additional patents tied to the new science.<\/p>\n\n\n\n These later-filed patents don\u2019t extend the life of the original product. A new patent on a long-acting injectable version of a therapy doesn\u2019t change when the older pill version loses its exclusivity. Generics are still free to enter when the original patents expire. What the newer patents do is encourage companies to invest in improvements that give patients better options.<\/p>\n\n\n\n
\n\n\n\n